Dupixent was approved for treating COPD with raised blood eosinophils in the EU in July 2024. Dupixent was also approved for the COPD indication in China last week. Sanofi’s stock has gained 16.0% so ...
Data support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4 in a broad COPD ...
The FDA has approved Dupixent (dupilumab) as an add-on therapy for adults with poorly controlled COPD, especially those with ...
The following is a summary of “Comparative Effectiveness of qSOFA, CURB-65, and PSI in Predicting Pneumonia Hospitalization ...
The approval was supported by data from the 52-week, randomized, double-blind, multicenter, parallel-group, placebo-controlled, phase 3 trials BOREAS and NOTUS.
In adults with undiagnosed respiratory symptoms, dyspnea impact was worse in those with PRISm vs undiagnosed asthma or COPD.
Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...
Hurricane Helene's massive rains and flooding is a major health and safety risk for residents exposed to potential ...
China NMPA approves Sanofi & Regeneron’s Dupixent as an add-on maintenance treatment for adults with uncontrolled COPD: Paris Monday, September 30, 2024, 11:00 Hrs [IST] The Nat ...
The National Medical Products Administration approved Dupixent as an add-on maintenance treatment for adults with ...
The second annual World Oxygen Day, led by the COPD Foundation and supported by Nonin, will be held Oct. 2. The day brings together more than a dozen global patient advocacy organizations and ...
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback